Akeso’s chief financial officer Bing Wang told Bloomberg’s China Show in San Francisco that he feels “pretty good” about the odds of ivonescimab clearing the U.S. Food and Drug Administration. The antibody, co‑developed with Summit Therapeutics, represents the Chinese firm’s most advanced oncology candidate and a potential gateway to the American market.

U.S. regulators have grown wary of data gaps in submissions from Chinese developers, prompting firms to seek U.S. partners that can bolster trial design and compliance. By aligning with Summit, Akeso gains access to Western clinical expertise and a clearer path through the FDA’s rigorous review, a strategy echoed by peers chasing global scale.

Analysts will monitor the filing of Akeso’s Biologics License Application later this year, noting that a positive decision could unlock a multi‑billion‑dollar revenue stream and validate the China‑U.S. co‑development model. Investors should also watch for any Phase III readouts that could sway the FDA’s final judgment.